Literature DB >> 9210878

Heterozygous P0 knockout mice develop a peripheral neuropathy that resembles chronic inflammatory demyelinating polyneuropathy (CIDP).

M E Shy1, E Arroyo, J Sladky, D Menichella, H Jiang, W Xu, J Kamholz, S S Scherer.   

Abstract

Demyelinating peripheral neuropathies are clinically divided into inherited and acquired types. Inherited demyelinating neuropathies are caused by mutations in genes expressed by myelinating Schwann cells, whereas acquired ones, including chronic inflammatory demyelinating polyneuropathy (CIDP), are probably caused by autoimmune mechanisms. We find that heterozygous P0 knockout (P0+/-) mice develop a neuropathy that resembles CIDP. By one year of age, P0+/- mice develop severe, asymmetric slowing of motor nerves, with temporal dispersion or conduction block, which are features of acquired demyelinating neuropathies including CIDP. Moreover, morphological analysis of affected nerves reveals severe and selective demyelination of motor fibers, focal regions of demyelination, and inflammatory cells. These data suggest that immune-mediated mechanisms may contribute to the pathogenesis of the neuropathy in P0+/- mice.

Entities:  

Mesh:

Year:  1997        PMID: 9210878

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  25 in total

Review 1.  Neuroactive steroids: A therapeutic approach to maintain peripheral nerve integrity during neurodegenerative events.

Authors:  Emanuela Leonelli; Marinella Ballabio; Antonio Consoli; Ilaria Roglio; Valerio Magnaghi; Roberto C Melcangi
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance.

Authors:  C D Schmid; M Stienekemeier; S Oehen; F Bootz; J Zielasek; R Gold; K V Toyka; M Schachner; R Martini
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

3.  Central nervous system dysfunction in a mouse model of FA2H deficiency.

Authors:  Kathleen A Potter; Michael J Kern; George Fullbright; Jacek Bielawski; Steven S Scherer; Sabrina W Yum; Jian J Li; Hua Cheng; Xianlin Han; Jagadish Kummetha Venkata; P Akbar Ali Khan; Bärbel Rohrer; Hiroko Hama
Journal:  Glia       Date:  2011-04-13       Impact factor: 7.452

4.  Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy.

Authors:  Hye-Jung Kim; Cha-Gyun Jung; Mark A Jensen; Danuta Dukala; Betty Soliven
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

5.  Myelin abnormality in Charcot-Marie-Tooth type 4J recapitulates features of acquired demyelination.

Authors:  Bo Hu; Megan McCollum; Vignesh Ravi; Sezgi Arpag; Daniel Moiseev; Ryan Castoro; Bret Mobley; Bryan Burnette; Carly Siskind; John Day; Robin Yawn; Shawna Feely; Yuebing Li; Qing Yan; Michael Shy; Jun Li
Journal:  Ann Neurol       Date:  2018-03-30       Impact factor: 10.422

Review 6.  Animal models of autoimmune neuropathy.

Authors:  Betty Soliven
Journal:  ILAR J       Date:  2014

Review 7.  Role of immune cells in animal models for inherited peripheral neuropathies.

Authors:  Chi Wang Ip; Antje Kroner; Stefan Fischer; Martin Berghoff; Igor Kobsar; Mathias Mäurer; Rudolf Martini
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

8.  PMP22 expression in dermal nerve myelin from patients with CMT1A.

Authors:  Istvan Katona; Xingyao Wu; Shawna M E Feely; Stephanie Sottile; Carly E Siskind; Lindsey J Miller; Michael E Shy; Jun Li
Journal:  Brain       Date:  2009-05-15       Impact factor: 13.501

9.  Conduction block in PMP22 deficiency.

Authors:  Yunhong Bai; Xuebao Zhang; Istvan Katona; Mario Andre Saporta; Michael E Shy; Heather A O'Malley; Lori L Isom; Ueli Suter; Jun Li
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

Review 10.  Role of immune cells in animal models for inherited neuropathies: facts and visions.

Authors:  Mathias Mäurer; Igor Kobsar; Martin Berghoff; Christoph D Schmid; Stefano Carenini; Rudolf Martini
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.